Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission
Michael T White, Stephan Karl, Katherine E Battle, Simon I Hay, Ivo Mueller, Azra C Ghani, Michael T White, Stephan Karl, Katherine E Battle, Simon I Hay, Ivo Mueller, Azra C Ghani
Abstract
Plasmodium vivax relapse infections occur following activation of latent liver-stages parasites (hypnozoites) causing new blood-stage infections weeks to months after the initial infection. We develop a within-host mathematical model of liver-stage hypnozoites, and validate it against data from tropical strains of P. vivax. The within-host model is embedded in a P. vivax transmission model to demonstrate the build-up of the hypnozoite reservoir following new infections and its depletion through hypnozoite activation and death. The hypnozoite reservoir is predicted to be over-dispersed with many individuals having few or no hypnozoites, and some having intensely infected livers. Individuals with more hypnozoites are predicted to experience more relapses and contribute more to onwards P. vivax transmission. Incorporating hypnozoite killing drugs such as primaquine into first-line treatment regimens is predicted to cause substantial reductions in P. vivax transmission as individuals with the most hypnozoites are more likely to relapse and be targeted for treatment.
Keywords: epidemiology; global health; human; malaria; mathematical; model; relapse; vivax.
Conflict of interest statement
SIH: Reviewing editor, eLife.
The other authors declare that no competing interests exist.
Figures
References
- Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, Flegg JA, Das D, Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin PJ, Dondorp AM, Day NP, White NJ, Tracking Resistance to ArtemisininCollaboration (TRAC) Spread of artemisinin resistance in Plasmodium falciparum nalaria. The New England Journal of Medicine. 2014;371:411–423. doi: 10.1056/NEJMoa1314981.
- Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, Van Boeckel TP, Messina JP, Shanks GD, Smith DL, Baird JK, Hay SI. Geographical variation in Plasmodium vivax relapse. Malaria Journal. 2014;13:144. doi: 10.1186/1475-2875-13-144.
- Beier JC, Davis JR, Vaughan JA, Noden BH, Beier MS. Quantitation of Plasmodium-falciparum sporozoites transmitted invitro by experimentally infected Anopheles-gambiae and Anopheles-stephensi. The American Journal of Tropical Medicine and Hygiene. 1991;44:564–570.
- Berliner RW, Earle DP, Taggart JV, Welch WJ, Zubrod CG, Knowlton P, Atchley JA, Shannon JA. Studies on the chemotherapy of the human malarias. vii. the antimalarial activity of pamaquine. The Journal of Clinical Investigation. 1948;27:108–113. doi: 10.1172/JCI101947.
- Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic D, Samol L, de Lazzari E, Del Portillo HA, Siba P, Alonso PL, Bassat Q, Mueller I. Relapses contribute significantly to the risk of P. vivax infection and disease in Papua New Guinean children 1-5 years of age. The Journal of Infectious Diseases. 2012;206:1771–1780. doi: 10.1093/infdis/jis580.
- Bharti AR, Chuquiyauri R, Brouwer KC, Stancil J, Lin J, Llanos-Cuentas A, Vinetz JM. Experimental infection of the neotropical malaria vector Anopheles darlingi by human patient-derived Plasmodium vivax in the Peruvian Amazon. The American Journal of Tropical Medicine and Hygiene. 2006;75:610–616.
- Chamchod F, Beier JC. Modeling Plasmodium vivax: relapses, treatment, seasonality, and G6PD deficiency. Journal of Theoretical Biology. 2013;7:25–34. doi: 10.1016/j.jtbi.2012.08.024.
- Coatney GR, Cooper WC, Young MD. Studies in human malaria. XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of Plasmodium vivax. Journal of the National Malaria Society. 1950;9:381–396.
- Collins WE, Jeffery GM, Roberts JM. A retrospective examination of anemia during infection of humans with Plasmodium vivax. The American Journal of Tropical Medicine and Hygiene. 2003;68:410–412.
- Coura JR, Suarez-Mutis M, Ladeia-Andrade S. A new challenge for malaria control in Brazil: asymptomatic Plasmodium infection - a review. Memorias Do Instituto Oswaldo Cruz. 2006;101:229–237.
- Dezoysa AP, Mendis C, Gamagemendis AC, Weerasinghe S, Herath PR, Mendis KN. A mathematical model for Plasmodium vivax malaria transmission - estimation of the impact of transmission-blocking immunity in an endemic area. Bulletin of the World Health Organization. 1991;69:725–734.
- Dietz K, Molineaux L. A malaria model tested in the African savannah. Ninth International Congress on Tropical Medicine and Malaria Athens Volume 1 Abstracts of Invited Papers. 1973:297.
- Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. The Lancet Infectious Diseases. 2010;10:405–416. doi: 10.1016/S1473-3099(10)70079-7.
- Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, White NJ, Price RN. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clinical Infectious Diseases. 2011;52:612–620. doi: 10.1093/cid/ciq249.
- Garrett-Jones C. The human blood index of malaria vectors in relation to epidemiological assessment. Bulletin of the World Health Organization. 1964;30:241–261.
- Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HF, Price RN, Müeller I, Baird JK, Hay SI. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLOS Neglected Tropical Diseases. 2012;6:e1814. doi: 10.1371/journal.pntd.0001814.
- Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, Tatem AJ, Hay SI. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malaria Journal. 2011a;10:378. doi: 10.1186/1475-2875-10-378.
- Gething PW, Van Boeckel TP, Smith DL, Guerra CA, Patil AP, Snow RW, Hay SI. Modelling the global constraints of temperature on transmission of Plasmodium falciparum and P. vivax. Parasites and Vectors. 2011b;4:92. doi: 10.1186/1756-3305-4-92.
- Hankey DD, Jones R, Jnr, Coatney GR, Alving AS, Coker WG, Garrison PL, Donovan WN. Korean vivax malaria. I. Natural history and response to chloroquine. The American Journal of Tropical Medicine and Hygiene. 1953;2:958–969.
- Harris I, Sharrock WW, Bain LM, Gray KA, Bobogare A, Boaz L, Lilley K, Krause D, Vallely A, Johnson ML, Gatton ML, Shanks GD, Cheng Q. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malaria Journal. 2010;9:254. doi: 10.1186/1475-2875-9-254.
- Horing RO. Induced and war malaria. The Journal of Tropical Medicine and Hygiene. 1947;50:150–159.
- Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Advances in Parasitology. 2013;81:133–201. doi: 10.1016/B978-0-12-407826-0.00004-7. In: Hay SI, Price R, Baird JK, editors. Epidemiology of Plasmodium vivax: history, hiatus and hubris, Pt B.
- Hulden L, Hulden L. Activation of the hypnozoite: a part of Plasmodium vivax life cycle and survival. Malaria Journal. 2011;10:90. doi: 10.1186/1475-2875-10-90.
- Ishikawa H, Ishii A, Nagai N, Ohmae H, Harada M, Suguri S, Leafasia J. A mathematical model for the transmission of Plasmodium vivax malaria. Parasitology International. 2003;52:81–93. doi: 10.1016/S1383-5769(02)00084-3.
- Kelly-Hope LA, McKenzie FE. The multiplicity of malaria transmission: a review of entomological inoculation rate measurements and methods across sub-Saharan Africa. Malaria Journal. 2009;8:19. doi: 10.1186/1475-2875-8-19.
- Kim S, Nguon C, Guillard B, Duong S, Chy S, Sum S, Nhem S, Bouchier C, Tichit M, Christophel E, Taylor WR, Baird JK, Menard D. Performance of the CareStart (TM) G6PD deficiency screening test, a point-of-care diagnostic for primaquine therapy screening. PLOS ONE. 2011;6:e28357. doi: 10.1371/journal.pone.0028357.
- Koepfli C, Ross A, Kiniboro B, Smith TA, Zimmerman PA, Siba P, Mueller I, Felger I. Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLOS Neglected Tropical Diseases. 2011;5:e1424. doi: 10.1371/journal.pntd.0001424.
- Koepfli C, Colborn KL, Kiniboro B, Lin E, Speed TP, Siba PM, Felger I, Mueller I. A high force of Plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in Papua New Guinean children. PLOS Neglected Tropical Diseases. 2013;7:e2403. doi: 10.1371/journal.pntd.0002403.
- Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Möhrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049–1058. doi: 10.1016/S0140-6736(13)62568-4.
- Lover AA, Coker RJ. Quantifying effect of geographic location on epidemiology of Plasmodium vivax malaria. Emerging Infectious Diseases. 2013;19:1058–1065. doi: 10.3201/eid1907.121674.
- Lover AA, Zhao X, Gao Z, Coker RJ, Cook AR. The distribution of incubation and relapse times in experimental human infections with the malaria parasite Plasmodium vivax. BMC Infectious Diseases. 2014;14:539. doi: 10.1186/1471-2334-14-539.
- Macdonald G. The analysis of equilibrium in malaria. Tropical Diseases Bulletin. 1952a;49:813–829.
- Macdonald G. The analysis of the sporozoite rate. Tropical Diseases Bulletin. 1952b;49:569–586.
- Malato Y, Naqvi S, Schuermann N, Ng R, Wang B, Zape J, Kay MA, Grimm D, Willenbring H. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. The Journal of Clinical Investigation. 2011;121:4850–4860. doi: 10.1172/JCI59261.
- malERA Consultative Group on Diagnoses and Diagnostics A research agenda for malaria eradication: diagnoses and diagnostics. PLOS Medicine. 2011;8:e1000396. doi: 10.1371/journal.pmed.1000396.
- malERA Consultative Group on Modeling A research agenda for malaria eradication: modeling. PLOS Medicine. 2011;8:e1000403. doi: 10.1371/journal.pmed.1000403.
- Medica DL, Sinnis P. Quantitative dynamics of Plasmodium yoelii sporozoite transmission by infected Anopheline mosquitoes. Infection and Immunity. 2005;73:4363–4369. doi: 10.1128/IAI.73.7.4363-4369.2005.
- Molineaux L, Diebner HH, Eichner M, Collins WE, Jeffery GM, Dietz K. Plasmodium falciparum parasitaemia described by a new mathematical model. Parasitology. 2001;122:379–391. doi: 10.1017/S0031182001007533.
- Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. The Lancet Infectious Diseases. 2009a;9:555–566. doi: 10.1016/S1473-3099(09)70177-X.
- Mueller I, Galinski MR, Tsuboi T, Arevalo-Herrera M, Collins WE, King CL. Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targets. Advances in Parasitology. 2013;81:77–131. doi: 10.1016/B978-0-12-407826-0.00003-5.
- Mueller I, Widmer S, Michel D, Maraga S, McNamara DT, Kiniboro B, Sie A, Smith TA, Zimmerman PA. High sensitivity detection of Plasmodium species reveals positive correlations between infections of different species, shifts in age distribution and reduced local variation in Papua New Guinea. Malaria Journal. 2009b;8:41. doi: 10.1186/1475-2875-8-41.
- Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2014;14:982–991. doi: 10.1016/S1473-3099.
- Reiner RC, Jnr, Perkins TA, Barker CM, Niu T, Fernando Chaves L, Ellis AM, George DB, Le Menach A, Pulliam JR, Bisanzio D, Buckee C, Chiyaka C, Cummings DA, Garcia AJ, Gatton ML, Gething PW, Hartley DM, Johnston G, Klein EY, Michael E, Lindsay SW, Lloyd AL, Pigott DM, Reisen WK, Ruktanonchai N, Singh BK, Tatem AJ, Kitron U, Hay SI, Scott TW, Smith DL. A systematic review of mathematical models of mosquito-borne pathogen transmission: 1970-2010. Journal of the Royal Society, Interface. 2013;10:20120921. doi: 10.1098/rsif.2012.0921.
- Roy M, Bouma MJ, Ionides EL, Dhiman RC, Pascual M. The potential elimination of Plasmodium vivax malaria by relapse treatment: insights from a transmission model and surveillance data from NW India. PLOS Neglected Tropical Diseases. 2013;7:e1979. doi: 10.1371/journal.pntd.0001979.
- Sattabongkot J, Tsuboi T, Zollner GE, Sirichaisinthop J, Cui LW. Plasmodium vivax transmission: chances for control? Trends in Parasitology. 2004;20:192–198. doi: 10.1016/j.pt.2004.02.001.
- Shanks GD, White NJ. The activation of vivax malaria hypnozoites by infectious diseases. The Lancet Infectious Diseases. 2013;13:900–906. doi: 10.1016/S1473-3099(13)70095-1.
- Smith DL, Battle KE, Hay SI, Barker CM, Scott TW, McKenzie FE. Ross, Macdonald, and a theory for the dynamics and control of mosquito-transmitted pathogens. PLOS Pathogens. 2012;8:e1002588. doi: 10.1371/journal.ppat.1002588.
- Smith DL, Drakeley CJ, Chiyaka C, Hay SI. A quantitative analysis of transmission efficiency versus intensity for malaria. Nature Communications. 2010;1:108. doi: 10.1038/ncomms1107.
- Smith DL, Dushoff J, Snow RW, Hay SI. The entomological inoculation rate and Plasmodium falciparum infection in African children. Nature. 2005;438:492–495. doi: 10.1038/nature04024.
- Smith DL, Perkins TA, Reiner RC, Jnr, Barker CM, Niu T, Chaves LF, Ellis AM, George DB, Le Menach A, Pulliam JR, Bisanzio D, Buckee C, Chiyaka C, Cummings DA, Garcia AJ, Gatton ML, Gething PW, Hartley DM, Johnston G, Klein EY, Michael E, Lloyd AL, Pigott DM, Reisen WK, Ruktanonchai N, Singh BK, Stoller J, Tatem AJ, Kitron U, Godfray HC, Cohen JM, Hay SI, Scott TW. Recasting the theory of mosquito-borne pathogen transmission dynamics and control. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2014;108:185–197. doi: 10.1093/trstmh/tru026.
- Snounou G, White NJ. The co-existence of Plasmodium: sidelights from falciparum and vivax malaria in Thailand. Trends in Parasitology. 2004;20:333–339. doi: 10.1016/j.pt.2004.05.004.
- Tarning J, Thana P, Phyo AP, Lwin KM, Hanpithakpong W, Ashley EA, Day NP, Nosten F, White NJ. Population pharmacokinetics and antimalarial pharmacodynamics of piperaquine in patients with Plasmodium vivax malaria in Thailand. CPT: Pharmacometrics & Systems Pharmacology. 2014;3:e132. doi: 10.1038/psp.2014.29.
- Wearing HJ, Rohani P, Keeling MJ. Appropriate models for the management of infectious diseases. PLOS Medicine. 2005;2:e174. doi: 10.1371/journal.pmed.0020174.
- Wells TN, Burrows JN, Baird JK. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends in Parasitology. 2010;26:145–151. doi: 10.1016/j.pt.2009.12.005.
- White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, Ockenhouse CF, Ghani AC. The relationship between RTS, S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. PLOS ONE. 2013;8:e61395. doi: 10.1371/journal.pone.0061395.
- White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malaria Journal. 2011;10:297. doi: 10.1186/1475-2875-10-297.
Source: PubMed